CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS

被引：0
|
作者：
Kato, Yukio [1 ]
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [21] LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38
    CHABOT, GG
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (06) : 463 - 472
  • [22] Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride
    Takara, Kohji
    Tada, Noriaki
    Yoshikawa, Eri
    Yamamoto, Kazuhiro
    Horibe, Sayo
    Sakaeda, Toshiyuki
    Nishiguchi, Kohshi
    Ohnishi, Noriaki
    Yokoyama, Teruyoshi
    CANCER LETTERS, 2009, 278 (01) : 88 - 96
  • [23] Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice
    Mallick, Pankajini
    Shah, Pranav
    Gandhi, Adarsh
    Ghose, Romi
    LIFE SCIENCES, 2015, 139 : 132 - 138
  • [24] Role of Mrp3-mediated efflux in systemic exposure of SN-38, the active metabolite of irinotecan
    Kitamura, Yoshiaki
    Kusuhara, Hiroyuki
    Sugiyama, Yuichi
    DRUG METABOLISM REVIEWS, 2010, 42 : 288 - 288
  • [25] Effective irinotecan (CPT-11)-containing liposomes: Intraliposomal conversion to the active metabolite SN-38
    Sadzuka, Y
    Hirotsu, S
    Hirota, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (02): : 226 - 232
  • [26] Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy
    Irie, Kei
    Okada, Akira
    Masuda, Yoshio
    Fukushima, Keizo
    Sugioka, Nobuyuki
    Okuda, Chiyuki
    Hata, Akito
    Kaji, Reiko
    Okada, Yutaka
    Katakami, Nobuyuki
    Fukushima, Shoji
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 865 - 868
  • [27] Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue
    Shirou Itagaki
    Yoshinobu Sumi
    Soji Shimamoto
    Tatsuya Itoh
    Takeshi Hirano
    Isao Takemoto
    Ken Iseki
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 502 - 506
  • [28] Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue
    Itagaki, S
    Sumi, Y
    Shimamoto, S
    Itoh, T
    Hirano, T
    Takemoto, I
    Iseki, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (05) : 502 - 506
  • [29] Identification of a new metabolite of CPT-11 (irinotecan). Biosynthesis and activation to SN-38 by human hepatic microsomes
    Haaz, MC
    Dodds, HM
    Riou, JF
    Riche, C
    Rivory, LP
    Robert, J
    ANNALS OF ONCOLOGY, 1998, 9 : 58 - 59
  • [30] Liposomalization of SN-38 as active metabolite of CPT-11
    Sadzuka, Y
    Takabe, H
    Sonobe, T
    JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) : 453 - 459
12345